Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment

Atherosclerosis

Volumn 209, Issue 1, 2010, Pages 178-183

  Stojakovic, Tatjana ^a   Claudel, Thierry ^a   Putz Bankuti, Csilla ^a   Fauler, Günter ^a   Scharnagl, Hubert ^a   Wagner, Martin ^a   Sourij, Harald ^a   Stauber, Rudolf E ^a   Winkler, Karl ^b   März, Winfried ^a,c   Wascher, Thomas C ^a,d   Trauner, Michael ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF FREIBURG   (Germany)

^c SYNLAB ACADEMY   (Germany)

^d HANUSCH HOSPITAL   (Austria)

Author keywords

Atherosclerosis; Cholestasis; Hypercholesterolemia; Primary biliary cirrhosis; Statins; Vascular function

Indexed keywords

ALKALINE PHOSPHATASE; ATORVASTATIN; IMMUNOGLOBULIN G; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTERIAL STIFFNESS; ARTERY INTIMA PROLIFERATION; ARTICLE; BRACHIAL ARTERY; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CAROTID ARTERY; CHOLESTASIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN SYNTHESIS INHIBITION; SIDE EFFECT; VASODILATATION;

BLOOD VESSELS; CARDIOVASCULAR DISEASES; CHOLESTASIS; CHOLESTEROL; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES;

EID: 77049089696     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.08.052     Document Type: Article

References (34)

1. Crosignani A., Battezzati P.M., Invernizzi P., Selmi C., Prina E., and Podda M. Clinical features and management of primary biliary cirrhosis. World J Gastroenterol 14 (2008) 3313-3327
2. Kaplan M.M., and Gershwin M.E. Primary biliary cirrhosis. N Engl J Med 353 (2005) 1261-1273
3. Trauner M., and Boyer J.L. Cholestatic syndromes. Curr Opin Gastroenterol 19 (2003) 216-231
4. Sorokin A., Brown J.L., and Thompson P.D. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. Atherosclerosis 194 (2007) 293-299
5. Allocca M., Crosignani A., Gritti A., et al. Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. Gut 55 (2006) 1795-1800
6. Chauhan S.S., and Zucker S.D. Hypercholesterolemia in primary biliary cirrhosis: getting to the heart of the matter?. Gastroenterology 124 (2003) 854-856
7. Longo M., Crosignani A., Battezzati P.M., et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut 51 (2002) 265-269
8. Solaymani-Dodaran M., Aithal G.P., Card T., and West J. Risk of cardiovascular and cerebrovascular events in primary biliary cirrhosis: a population-based cohort study. Am J Gastroenterol 103 (2008) 1-5
9. Su T.C., Hwang J.J., and Kao J.H. Hypercholesterolemia in primary biliary cirrhosis. N Engl J Med 357 (2007) 1561-1562
10. Balmer M.L., and Dufour J.F. Treatment of hypercholesterolemia in patients with primary biliary cirrhosis might be more beneficial than indicated. Swiss Med Wkly 138 (2008) 415-419
11. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
12. Argo C.K., Loria P., Caldwell S.H., and Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither?. Hepatology 48 (2008) 662-669
13. Del Puppo M., Galli Kienle M., Crosignani A., et al. Cholesterol metabolism in primary biliary cirrhosis during simvastatin and UDCA administration. J Lipid Res 42 (2001) 437-441
14. Ritzel U., Leonhardt U., Nather M., Schafer G., Armstrong V.W., and Ramadori G. Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. J Hepatol 36 (2002) 454-458
15. Stojakovic T., Putz-Bankuti C., Fauler G., et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 46 (2007) 776-784
16. Bachorik P.S., and Ross J.W. National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. Clin Chem 41 (1995) 1414-1420
17. Wascher T.C., Paulweber B., Malaimare L., et al. Associations of a human G protein beta3 subunit dimorphism with insulin resistance and carotid atherosclerosis. Stroke 34 (2003) 605-609
18. Wascher T.C., Schmoelzer I., Wiegratz A., et al. Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance. Eur J Clin Invest 35 (2005) 551-557
19. Millasseau S.C., Kelly R.P., Ritter J.M., and Chowienczyk P.J. Determination of age-related increases in large artery stiffness by digital pulse contour analysis. Clin Sci (Lond) 103 (2002) 371-377
20. Arca M. Atorvastatin: a safety and tolerability profile. Drugs 67 suppl. 1 (2007) 63-69
21. Abu Rajah M.A., and Kaplan M.M. Statin use in patients with primary biliary cirrhosis (PBC): are they safe?. Gastroenterology 132 suppl. 2 (2007) A732-1732
22. Lewis J.H., Mortensen M.E., Zweig S., Fusco M.J., Medoff J.R., and Belder R. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 46 (2007) 1453-1463
23. Browning J.D. Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology 44 (2006) 466-471
24. Onofrei M.D., Butler K.L., Fuke D.C., and Miller H.B. Safety of statin therapy in patients with preexisting liver disease. Pharmacotherapy 28 (2008) 522-529
25. Lindor K. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. N Engl J Med 357 (2007) 1524-1529
26. Steinberg D. The LDL modification hypothesis of atherogenesis: an update. J Lipid Res 50 suppl. (2009) S376-381
27. Marz W., Scharnagl H., Winkler K., et al. Low-density lipoprotein triglycerides associated with low-grade systemic inflammation, adhesion molecules, and angiographic coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health study. Circulation 110 (2004) 3068-3074
28. Cybulsky M.I., Iiyama K., Li H., et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 107 (2001) 1255-1262
29. Dansky H.M., Barlow C.B., Lominska C., et al. Adhesion of monocytes to arterial endothelium and initiation of atherosclerosis are critically dependent on vascular cell adhesion molecule-1 gene dosage. Arterioscler Thromb Vasc Biol 21 (2001) 1662-1667
30. Bots M.L. Carotid intima-media thickness as a surrogate marker for cardiovascular disease in intervention studies. Curr Med Res Opin 22 (2006) 2181-2190
31. Lorenz M.W., Markus H.S., Bots M.L., Rosvall M., and Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115 (2007) 459-467
32. Duprez D.A., and Cohn J.N. Arterial stiffness as a risk factor for coronary atherosclerosis. Curr Atheroscler Rep 9 (2007) 139-144
33. Mattace-Raso F.U., van der Cammen T.J., Hofman A., et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation 113 (2006) 657-663
34. Wilkinson I.B., Hall I.R., MacCallum H., et al. Pulse-wave analysis: clinical evaluation of a noninvasive, widely applicable method for assessing endothelial function. Arterioscler Thromb Vasc Biol 22 (2002) 147-152